Targeted gene panel sequencing for the rapid diagnosis of acutely ill infants

Luca Brunelli, Sabrina M. Jenkins, James M. Gudgeon, Steven B. Bleyl, Christine E. Miller, Tatiana Tvrdik, Shale A. Dames, Betsy Ostrander, Josue A.F. Daboub, Brandon A. Zielinski, Erin K. Zinkhan, Hunter R. Underhill, Theodore Wilson, Joshua L. Bonkowsky, Christian C. Yost, Lorenzo D. Botto, Justin Jenkins, Theodore J. Pysher, Pinar Bayrak-Toydemir, Rong Mao

Research output: Contribution to journalArticle

Abstract

Background: Exome/genome sequencing (ES/GS) have been recently used in neonatal and pediatric/cardiac intensive care units (NICU and PICU/CICU) to diagnose and care for acutely ill infants, but the effectiveness of targeted gene panels for these purposes remains unknown. Methods: RapSeq, a newly developed panel targeting 4,503 disease-causing genes, was employed on selected patients in our NICU/PICU/CICU. Twenty trios were sequenced from October 2015 to March 2017. We assessed diagnostic yield, turnaround times, and clinical consequences. Results: A diagnosis was made in 10/20 neonates (50%); eight had de novo variants (ASXL1, CHD, FBN1, KMT2D, FANCB, FLNA, PAX3), one was a compound heterozygote for CHAT, and one had a maternally inherited GNAS variant. Preliminary reports were generated by 9.6 days (mean); final reports after Sanger sequencing at 16.3 days (mean). In all positive infants, the diagnosis changed management. In a case with congenital myasthenia, diagnosis and treatment occurred at 17 days versus 7 months in a historical control. Conclusions: This study shows that a gene panel that includes the majority of known disease-causing genes can rapidly identify a diagnosis in a large number of tested infants. Due to simpler deployment and interpretation and lower costs, this approach might represent an alternative to ES/GS in the NICU/PICU/CICU.

Original languageEnglish (US)
Article numbere00796
JournalMolecular Genetics and Genomic Medicine
Volume7
Issue number7
DOIs
StatePublished - Jul 1 2019

Fingerprint

Genes
Congenital Myasthenic Syndromes
Exome
Pediatric Intensive Care Units
Heterozygote
Newborn Infant
Genome
Costs and Cost Analysis
Therapeutics
Maternal Inheritance

Keywords

  • genetic diagnosis
  • neonatology
  • newborn
  • precision medicine
  • rapid sequencing

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Genetics(clinical)

Cite this

Brunelli, L., Jenkins, S. M., Gudgeon, J. M., Bleyl, S. B., Miller, C. E., Tvrdik, T., ... Mao, R. (2019). Targeted gene panel sequencing for the rapid diagnosis of acutely ill infants. Molecular Genetics and Genomic Medicine, 7(7), [e00796]. https://doi.org/10.1002/mgg3.796

Targeted gene panel sequencing for the rapid diagnosis of acutely ill infants. / Brunelli, Luca; Jenkins, Sabrina M.; Gudgeon, James M.; Bleyl, Steven B.; Miller, Christine E.; Tvrdik, Tatiana; Dames, Shale A.; Ostrander, Betsy; Daboub, Josue A.F.; Zielinski, Brandon A.; Zinkhan, Erin K.; Underhill, Hunter R.; Wilson, Theodore; Bonkowsky, Joshua L.; Yost, Christian C.; Botto, Lorenzo D.; Jenkins, Justin; Pysher, Theodore J.; Bayrak-Toydemir, Pinar; Mao, Rong.

In: Molecular Genetics and Genomic Medicine, Vol. 7, No. 7, e00796, 01.07.2019.

Research output: Contribution to journalArticle

Brunelli, L, Jenkins, SM, Gudgeon, JM, Bleyl, SB, Miller, CE, Tvrdik, T, Dames, SA, Ostrander, B, Daboub, JAF, Zielinski, BA, Zinkhan, EK, Underhill, HR, Wilson, T, Bonkowsky, JL, Yost, CC, Botto, LD, Jenkins, J, Pysher, TJ, Bayrak-Toydemir, P & Mao, R 2019, 'Targeted gene panel sequencing for the rapid diagnosis of acutely ill infants', Molecular Genetics and Genomic Medicine, vol. 7, no. 7, e00796. https://doi.org/10.1002/mgg3.796
Brunelli, Luca ; Jenkins, Sabrina M. ; Gudgeon, James M. ; Bleyl, Steven B. ; Miller, Christine E. ; Tvrdik, Tatiana ; Dames, Shale A. ; Ostrander, Betsy ; Daboub, Josue A.F. ; Zielinski, Brandon A. ; Zinkhan, Erin K. ; Underhill, Hunter R. ; Wilson, Theodore ; Bonkowsky, Joshua L. ; Yost, Christian C. ; Botto, Lorenzo D. ; Jenkins, Justin ; Pysher, Theodore J. ; Bayrak-Toydemir, Pinar ; Mao, Rong. / Targeted gene panel sequencing for the rapid diagnosis of acutely ill infants. In: Molecular Genetics and Genomic Medicine. 2019 ; Vol. 7, No. 7.
@article{fa25dcfb427542a89000b6d218810e65,
title = "Targeted gene panel sequencing for the rapid diagnosis of acutely ill infants",
abstract = "Background: Exome/genome sequencing (ES/GS) have been recently used in neonatal and pediatric/cardiac intensive care units (NICU and PICU/CICU) to diagnose and care for acutely ill infants, but the effectiveness of targeted gene panels for these purposes remains unknown. Methods: RapSeq, a newly developed panel targeting 4,503 disease-causing genes, was employed on selected patients in our NICU/PICU/CICU. Twenty trios were sequenced from October 2015 to March 2017. We assessed diagnostic yield, turnaround times, and clinical consequences. Results: A diagnosis was made in 10/20 neonates (50{\%}); eight had de novo variants (ASXL1, CHD, FBN1, KMT2D, FANCB, FLNA, PAX3), one was a compound heterozygote for CHAT, and one had a maternally inherited GNAS variant. Preliminary reports were generated by 9.6 days (mean); final reports after Sanger sequencing at 16.3 days (mean). In all positive infants, the diagnosis changed management. In a case with congenital myasthenia, diagnosis and treatment occurred at 17 days versus 7 months in a historical control. Conclusions: This study shows that a gene panel that includes the majority of known disease-causing genes can rapidly identify a diagnosis in a large number of tested infants. Due to simpler deployment and interpretation and lower costs, this approach might represent an alternative to ES/GS in the NICU/PICU/CICU.",
keywords = "genetic diagnosis, neonatology, newborn, precision medicine, rapid sequencing",
author = "Luca Brunelli and Jenkins, {Sabrina M.} and Gudgeon, {James M.} and Bleyl, {Steven B.} and Miller, {Christine E.} and Tatiana Tvrdik and Dames, {Shale A.} and Betsy Ostrander and Daboub, {Josue A.F.} and Zielinski, {Brandon A.} and Zinkhan, {Erin K.} and Underhill, {Hunter R.} and Theodore Wilson and Bonkowsky, {Joshua L.} and Yost, {Christian C.} and Botto, {Lorenzo D.} and Justin Jenkins and Pysher, {Theodore J.} and Pinar Bayrak-Toydemir and Rong Mao",
year = "2019",
month = "7",
day = "1",
doi = "10.1002/mgg3.796",
language = "English (US)",
volume = "7",
journal = "Molecular genetics & genomic medicine",
issn = "2324-9269",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - Targeted gene panel sequencing for the rapid diagnosis of acutely ill infants

AU - Brunelli, Luca

AU - Jenkins, Sabrina M.

AU - Gudgeon, James M.

AU - Bleyl, Steven B.

AU - Miller, Christine E.

AU - Tvrdik, Tatiana

AU - Dames, Shale A.

AU - Ostrander, Betsy

AU - Daboub, Josue A.F.

AU - Zielinski, Brandon A.

AU - Zinkhan, Erin K.

AU - Underhill, Hunter R.

AU - Wilson, Theodore

AU - Bonkowsky, Joshua L.

AU - Yost, Christian C.

AU - Botto, Lorenzo D.

AU - Jenkins, Justin

AU - Pysher, Theodore J.

AU - Bayrak-Toydemir, Pinar

AU - Mao, Rong

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Background: Exome/genome sequencing (ES/GS) have been recently used in neonatal and pediatric/cardiac intensive care units (NICU and PICU/CICU) to diagnose and care for acutely ill infants, but the effectiveness of targeted gene panels for these purposes remains unknown. Methods: RapSeq, a newly developed panel targeting 4,503 disease-causing genes, was employed on selected patients in our NICU/PICU/CICU. Twenty trios were sequenced from October 2015 to March 2017. We assessed diagnostic yield, turnaround times, and clinical consequences. Results: A diagnosis was made in 10/20 neonates (50%); eight had de novo variants (ASXL1, CHD, FBN1, KMT2D, FANCB, FLNA, PAX3), one was a compound heterozygote for CHAT, and one had a maternally inherited GNAS variant. Preliminary reports were generated by 9.6 days (mean); final reports after Sanger sequencing at 16.3 days (mean). In all positive infants, the diagnosis changed management. In a case with congenital myasthenia, diagnosis and treatment occurred at 17 days versus 7 months in a historical control. Conclusions: This study shows that a gene panel that includes the majority of known disease-causing genes can rapidly identify a diagnosis in a large number of tested infants. Due to simpler deployment and interpretation and lower costs, this approach might represent an alternative to ES/GS in the NICU/PICU/CICU.

AB - Background: Exome/genome sequencing (ES/GS) have been recently used in neonatal and pediatric/cardiac intensive care units (NICU and PICU/CICU) to diagnose and care for acutely ill infants, but the effectiveness of targeted gene panels for these purposes remains unknown. Methods: RapSeq, a newly developed panel targeting 4,503 disease-causing genes, was employed on selected patients in our NICU/PICU/CICU. Twenty trios were sequenced from October 2015 to March 2017. We assessed diagnostic yield, turnaround times, and clinical consequences. Results: A diagnosis was made in 10/20 neonates (50%); eight had de novo variants (ASXL1, CHD, FBN1, KMT2D, FANCB, FLNA, PAX3), one was a compound heterozygote for CHAT, and one had a maternally inherited GNAS variant. Preliminary reports were generated by 9.6 days (mean); final reports after Sanger sequencing at 16.3 days (mean). In all positive infants, the diagnosis changed management. In a case with congenital myasthenia, diagnosis and treatment occurred at 17 days versus 7 months in a historical control. Conclusions: This study shows that a gene panel that includes the majority of known disease-causing genes can rapidly identify a diagnosis in a large number of tested infants. Due to simpler deployment and interpretation and lower costs, this approach might represent an alternative to ES/GS in the NICU/PICU/CICU.

KW - genetic diagnosis

KW - neonatology

KW - newborn

KW - precision medicine

KW - rapid sequencing

UR - http://www.scopus.com/inward/record.url?scp=85068915324&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068915324&partnerID=8YFLogxK

U2 - 10.1002/mgg3.796

DO - 10.1002/mgg3.796

M3 - Article

VL - 7

JO - Molecular genetics & genomic medicine

JF - Molecular genetics & genomic medicine

SN - 2324-9269

IS - 7

M1 - e00796

ER -